Timing of two versus three doses of quadrivalent HPV vaccine and associated effectiveness against condyloma in Sweden: a nationwide cohort study
ObjectiveTo assess incidence of condyloma after two doses of quadrivalent human papillomavirus (qHPV) vaccine, by time since first vaccine dose, in girls and women initiating vaccination before age 20 years.DesignRegister-based nationwide open cohort study.SettingSweden.ParticipantsGirls and women i...
Gespeichert in:
| Veröffentlicht in: | BMJ open 2017-06, Vol.7 (6), p.e015021-e015021 |
|---|---|
| Hauptverfasser: | , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | e015021 |
|---|---|
| container_issue | 6 |
| container_start_page | e015021 |
| container_title | BMJ open |
| container_volume | 7 |
| creator | F, Lamb E, Herweijer A, Ploner I, Uhnoo K, Sundström P, Sparén L, Arnheim-Dahlström |
| description | ObjectiveTo assess incidence of condyloma after two doses of quadrivalent human papillomavirus (qHPV) vaccine, by time since first vaccine dose, in girls and women initiating vaccination before age 20 years.DesignRegister-based nationwide open cohort study.SettingSweden.ParticipantsGirls and women initiating qHPV vaccination before age 20 years between 2006 and 2012. The study cohort included 264 498 girls, of whom 72 042 had received two doses of qHPV vaccine and 185 456 had received all three doses.Main outcome measureIncidence rate ratios (IRRs) of condyloma estimated by time between first and second doses of qHPV in months (m) and age at vaccination, adjusted for attained age.ResultsFor girls first vaccinated with two doses before the age of 17 years, the IRR of condyloma for 0–3 months between the first and second doses was 1.96 (95% CI 1.43 to 2.68) as compared with the standard three-dose schedule. The IRRs were 1.27 (95% CI 0.63 to 2.58) and 4.36 (95% CI 2.05 to 9.28) after receipt of two doses with 4–7 months and 8+ months between doses, respectively. For women first vaccinated after the age of 17 years, vaccination with two doses of qHPV vaccine and 0–3 months between doses was associated with an IRR of 2.12 (95% CI 1.62 to 2.77). For an interval of 4–7 months between doses, the IRR did not statistically significantly differ to the standard three-dose schedule (IRR=0.81, 95% CI 0.36 to 1.84). For women with 8+ months between dose 1 and dose 2 the IRR was 3.16 (95% CI 1.40 to 7.14).ConclusionA two-dose schedule for qHPV vaccine with 4–7 months between the first and second doses may be as effective against condyloma in girls and women initiating vaccination under 20 years as a three-dose schedule. Results from this nationwide study support immunogenicity data from clinical trials. |
| doi_str_mv | 10.1136/bmjopen-2016-015021 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_swepu</sourceid><recordid>TN_cdi_swepub_primary_oai_swepub_ki_se_496203</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2664174124</sourcerecordid><originalsourceid>FETCH-LOGICAL-b538t-546a57cb1a28ff1abbff5261458c8d285e398e6eaa8113e0a0181ab1234354353</originalsourceid><addsrcrecordid>eNqNktFqFDEUhgdRbKl9AkEC3ngzNckkmYwXgpRqhYKC1dtwZubMbtaZZJtkdtm38JHNsmtpvRBDIIec7_9JDn9RvGT0grFKvW2nlV-jKzllqqRMUs6eFKecClEqKuXTB_VJcR7jiuYlZCMlf16ccK0orVRzWvy6tZN1C-IHkraebDDEOZK0DIik9xHjvnM3Qx_sBkZ0iVx__UE20HXWIQHXE4jRdxYS9gSHAbtkN-gwRgILsC4m0nnX70Y_AbGOfNtij-4dAeIgWe-2tsdMLH1IJKa5370ong0wRjw_nmfF949Xt5fX5c2XT58vP9yUrax0KqVQIOuuZcD1MDBo22GQXDEhdad7riVWjUaFADrPCylQpjPFeCUqmXd1VpQH37jF9dyadbAThJ3xYM3x6meu0IhGcVpl_v2Bz50J-y6PIsD4SPa44-zSLPzGyLoSXDfZ4M3RIPi7GWMyk40djiM49HM0rKE6g6qpM_r6L3Tl5-DyOAxXSrBaMC7-RWWvuuZcUpap6kB1wccYcLh_MqNmHyVzjJLZR8kcopRVrx7-9l7zJzgZuDgAWf1fjr8BMsDXVQ</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1907722501</pqid></control><display><type>article</type><title>Timing of two versus three doses of quadrivalent HPV vaccine and associated effectiveness against condyloma in Sweden: a nationwide cohort study</title><source>BMJ Open Access Journals</source><source>MEDLINE</source><source>DOAJ Directory of Open Access Journals</source><source>Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals</source><source>PubMed Central</source><source>SWEPUB Freely available online</source><source>PubMed Central Open Access</source><creator>F, Lamb ; E, Herweijer ; A, Ploner ; I, Uhnoo ; K, Sundström ; P, Sparén ; L, Arnheim-Dahlström</creator><creatorcontrib>F, Lamb ; E, Herweijer ; A, Ploner ; I, Uhnoo ; K, Sundström ; P, Sparén ; L, Arnheim-Dahlström</creatorcontrib><description>ObjectiveTo assess incidence of condyloma after two doses of quadrivalent human papillomavirus (qHPV) vaccine, by time since first vaccine dose, in girls and women initiating vaccination before age 20 years.DesignRegister-based nationwide open cohort study.SettingSweden.ParticipantsGirls and women initiating qHPV vaccination before age 20 years between 2006 and 2012. The study cohort included 264 498 girls, of whom 72 042 had received two doses of qHPV vaccine and 185 456 had received all three doses.Main outcome measureIncidence rate ratios (IRRs) of condyloma estimated by time between first and second doses of qHPV in months (m) and age at vaccination, adjusted for attained age.ResultsFor girls first vaccinated with two doses before the age of 17 years, the IRR of condyloma for 0–3 months between the first and second doses was 1.96 (95% CI 1.43 to 2.68) as compared with the standard three-dose schedule. The IRRs were 1.27 (95% CI 0.63 to 2.58) and 4.36 (95% CI 2.05 to 9.28) after receipt of two doses with 4–7 months and 8+ months between doses, respectively. For women first vaccinated after the age of 17 years, vaccination with two doses of qHPV vaccine and 0–3 months between doses was associated with an IRR of 2.12 (95% CI 1.62 to 2.77). For an interval of 4–7 months between doses, the IRR did not statistically significantly differ to the standard three-dose schedule (IRR=0.81, 95% CI 0.36 to 1.84). For women with 8+ months between dose 1 and dose 2 the IRR was 3.16 (95% CI 1.40 to 7.14).ConclusionA two-dose schedule for qHPV vaccine with 4–7 months between the first and second doses may be as effective against condyloma in girls and women initiating vaccination under 20 years as a three-dose schedule. Results from this nationwide study support immunogenicity data from clinical trials.</description><identifier>ISSN: 2044-6055</identifier><identifier>EISSN: 2044-6055</identifier><identifier>DOI: 10.1136/bmjopen-2016-015021</identifier><identifier>PMID: 28600369</identifier><language>eng</language><publisher>England: BMJ Publishing Group LTD</publisher><subject>Adolescent ; Adult ; Age ; Cancer ; Child ; Cohort analysis ; Cohort Studies ; Condylomata Acuminata - epidemiology ; Condylomata Acuminata - prevention & control ; Disease ; Drug dosages ; Emigration ; Epidemiology ; Female ; Girls ; Health surveillance ; Human papillomavirus ; Humans ; Immunization Schedule ; Incidence ; Papillomavirus Infections - prevention & control ; Papillomavirus Vaccines - administration & dosage ; Population ; Public health ; Socioeconomic factors ; Sweden - epidemiology ; Systematic review ; Vaccines ; Womens health ; Young Adult</subject><ispartof>BMJ open, 2017-06, Vol.7 (6), p.e015021-e015021</ispartof><rights>Article author(s) (or their employer(s) unless otherwise stated in the text of the article) 2017. All rights reserved. No commercial use is permitted unless otherwise expressly granted.</rights><rights>2017 Article author(s) (or their employer(s) unless otherwise stated in the text of the article) 2017. All rights reserved. No commercial use is permitted unless otherwise expressly granted. This is an Open Access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/ Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.</rights><rights>Article author(s) (or their employer(s) unless otherwise stated in the text of the article) 2017. All rights reserved. No commercial use is permitted unless otherwise expressly granted. 2017</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-b538t-546a57cb1a28ff1abbff5261458c8d285e398e6eaa8113e0a0181ab1234354353</citedby><cites>FETCH-LOGICAL-b538t-546a57cb1a28ff1abbff5261458c8d285e398e6eaa8113e0a0181ab1234354353</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttp://bmjopen.bmj.com/content/7/6/e015021.full.pdf$$EPDF$$P50$$Gbmj$$Hfree_for_read</linktopdf><linktohtml>$$Uhttp://bmjopen.bmj.com/content/7/6/e015021.full$$EHTML$$P50$$Gbmj$$Hfree_for_read</linktohtml><link.rule.ids>230,314,550,723,776,780,860,881,27526,27527,27901,27902,53766,53768,77343,77374</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/28600369$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink><backlink>$$Uhttp://kipublications.ki.se/Default.aspx?queryparsed=id:136355206$$DView record from Swedish Publication Index$$Hfree_for_read</backlink></links><search><creatorcontrib>F, Lamb</creatorcontrib><creatorcontrib>E, Herweijer</creatorcontrib><creatorcontrib>A, Ploner</creatorcontrib><creatorcontrib>I, Uhnoo</creatorcontrib><creatorcontrib>K, Sundström</creatorcontrib><creatorcontrib>P, Sparén</creatorcontrib><creatorcontrib>L, Arnheim-Dahlström</creatorcontrib><title>Timing of two versus three doses of quadrivalent HPV vaccine and associated effectiveness against condyloma in Sweden: a nationwide cohort study</title><title>BMJ open</title><addtitle>BMJ Open</addtitle><description>ObjectiveTo assess incidence of condyloma after two doses of quadrivalent human papillomavirus (qHPV) vaccine, by time since first vaccine dose, in girls and women initiating vaccination before age 20 years.DesignRegister-based nationwide open cohort study.SettingSweden.ParticipantsGirls and women initiating qHPV vaccination before age 20 years between 2006 and 2012. The study cohort included 264 498 girls, of whom 72 042 had received two doses of qHPV vaccine and 185 456 had received all three doses.Main outcome measureIncidence rate ratios (IRRs) of condyloma estimated by time between first and second doses of qHPV in months (m) and age at vaccination, adjusted for attained age.ResultsFor girls first vaccinated with two doses before the age of 17 years, the IRR of condyloma for 0–3 months between the first and second doses was 1.96 (95% CI 1.43 to 2.68) as compared with the standard three-dose schedule. The IRRs were 1.27 (95% CI 0.63 to 2.58) and 4.36 (95% CI 2.05 to 9.28) after receipt of two doses with 4–7 months and 8+ months between doses, respectively. For women first vaccinated after the age of 17 years, vaccination with two doses of qHPV vaccine and 0–3 months between doses was associated with an IRR of 2.12 (95% CI 1.62 to 2.77). For an interval of 4–7 months between doses, the IRR did not statistically significantly differ to the standard three-dose schedule (IRR=0.81, 95% CI 0.36 to 1.84). For women with 8+ months between dose 1 and dose 2 the IRR was 3.16 (95% CI 1.40 to 7.14).ConclusionA two-dose schedule for qHPV vaccine with 4–7 months between the first and second doses may be as effective against condyloma in girls and women initiating vaccination under 20 years as a three-dose schedule. Results from this nationwide study support immunogenicity data from clinical trials.</description><subject>Adolescent</subject><subject>Adult</subject><subject>Age</subject><subject>Cancer</subject><subject>Child</subject><subject>Cohort analysis</subject><subject>Cohort Studies</subject><subject>Condylomata Acuminata - epidemiology</subject><subject>Condylomata Acuminata - prevention & control</subject><subject>Disease</subject><subject>Drug dosages</subject><subject>Emigration</subject><subject>Epidemiology</subject><subject>Female</subject><subject>Girls</subject><subject>Health surveillance</subject><subject>Human papillomavirus</subject><subject>Humans</subject><subject>Immunization Schedule</subject><subject>Incidence</subject><subject>Papillomavirus Infections - prevention & control</subject><subject>Papillomavirus Vaccines - administration & dosage</subject><subject>Population</subject><subject>Public health</subject><subject>Socioeconomic factors</subject><subject>Sweden - epidemiology</subject><subject>Systematic review</subject><subject>Vaccines</subject><subject>Womens health</subject><subject>Young Adult</subject><issn>2044-6055</issn><issn>2044-6055</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2017</creationdate><recordtype>article</recordtype><sourceid>9YT</sourceid><sourceid>ACMMV</sourceid><sourceid>EIF</sourceid><sourceid>BENPR</sourceid><sourceid>D8T</sourceid><recordid>eNqNktFqFDEUhgdRbKl9AkEC3ngzNckkmYwXgpRqhYKC1dtwZubMbtaZZJtkdtm38JHNsmtpvRBDIIec7_9JDn9RvGT0grFKvW2nlV-jKzllqqRMUs6eFKecClEqKuXTB_VJcR7jiuYlZCMlf16ccK0orVRzWvy6tZN1C-IHkraebDDEOZK0DIik9xHjvnM3Qx_sBkZ0iVx__UE20HXWIQHXE4jRdxYS9gSHAbtkN-gwRgILsC4m0nnX70Y_AbGOfNtij-4dAeIgWe-2tsdMLH1IJKa5370ong0wRjw_nmfF949Xt5fX5c2XT58vP9yUrax0KqVQIOuuZcD1MDBo22GQXDEhdad7riVWjUaFADrPCylQpjPFeCUqmXd1VpQH37jF9dyadbAThJ3xYM3x6meu0IhGcVpl_v2Bz50J-y6PIsD4SPa44-zSLPzGyLoSXDfZ4M3RIPi7GWMyk40djiM49HM0rKE6g6qpM_r6L3Tl5-DyOAxXSrBaMC7-RWWvuuZcUpap6kB1wccYcLh_MqNmHyVzjJLZR8kcopRVrx7-9l7zJzgZuDgAWf1fjr8BMsDXVQ</recordid><startdate>20170601</startdate><enddate>20170601</enddate><creator>F, Lamb</creator><creator>E, Herweijer</creator><creator>A, Ploner</creator><creator>I, Uhnoo</creator><creator>K, Sundström</creator><creator>P, Sparén</creator><creator>L, Arnheim-Dahlström</creator><general>BMJ Publishing Group LTD</general><general>BMJ Publishing Group</general><scope>9YT</scope><scope>ACMMV</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7RV</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>88G</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BENPR</scope><scope>BTHHO</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>K9-</scope><scope>K9.</scope><scope>KB0</scope><scope>M0R</scope><scope>M0S</scope><scope>M1P</scope><scope>M2M</scope><scope>NAPCQ</scope><scope>PIMPY</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>PSYQQ</scope><scope>Q9U</scope><scope>7X8</scope><scope>5PM</scope><scope>ADTPV</scope><scope>AOWAS</scope><scope>D8T</scope><scope>ZZAVC</scope></search><sort><creationdate>20170601</creationdate><title>Timing of two versus three doses of quadrivalent HPV vaccine and associated effectiveness against condyloma in Sweden: a nationwide cohort study</title><author>F, Lamb ; E, Herweijer ; A, Ploner ; I, Uhnoo ; K, Sundström ; P, Sparén ; L, Arnheim-Dahlström</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-b538t-546a57cb1a28ff1abbff5261458c8d285e398e6eaa8113e0a0181ab1234354353</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2017</creationdate><topic>Adolescent</topic><topic>Adult</topic><topic>Age</topic><topic>Cancer</topic><topic>Child</topic><topic>Cohort analysis</topic><topic>Cohort Studies</topic><topic>Condylomata Acuminata - epidemiology</topic><topic>Condylomata Acuminata - prevention & control</topic><topic>Disease</topic><topic>Drug dosages</topic><topic>Emigration</topic><topic>Epidemiology</topic><topic>Female</topic><topic>Girls</topic><topic>Health surveillance</topic><topic>Human papillomavirus</topic><topic>Humans</topic><topic>Immunization Schedule</topic><topic>Incidence</topic><topic>Papillomavirus Infections - prevention & control</topic><topic>Papillomavirus Vaccines - administration & dosage</topic><topic>Population</topic><topic>Public health</topic><topic>Socioeconomic factors</topic><topic>Sweden - epidemiology</topic><topic>Systematic review</topic><topic>Vaccines</topic><topic>Womens health</topic><topic>Young Adult</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>F, Lamb</creatorcontrib><creatorcontrib>E, Herweijer</creatorcontrib><creatorcontrib>A, Ploner</creatorcontrib><creatorcontrib>I, Uhnoo</creatorcontrib><creatorcontrib>K, Sundström</creatorcontrib><creatorcontrib>P, Sparén</creatorcontrib><creatorcontrib>L, Arnheim-Dahlström</creatorcontrib><collection>BMJ Open Access Journals</collection><collection>BMJ Journals:Open Access</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Nursing & Allied Health Database</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>Psychology Database (Alumni)</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central Essentials</collection><collection>ProQuest Central</collection><collection>BMJ Journals</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>Consumer Health Database (Alumni Edition)</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Nursing & Allied Health Database (Alumni Edition)</collection><collection>Consumer Health Database</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>ProQuest Psychology</collection><collection>Nursing & Allied Health Premium</collection><collection>Publicly Available Content Database</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>ProQuest One Psychology</collection><collection>ProQuest Central Basic</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><collection>SwePub</collection><collection>SwePub Articles</collection><collection>SWEPUB Freely available online</collection><collection>SwePub Articles full text</collection><jtitle>BMJ open</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>F, Lamb</au><au>E, Herweijer</au><au>A, Ploner</au><au>I, Uhnoo</au><au>K, Sundström</au><au>P, Sparén</au><au>L, Arnheim-Dahlström</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Timing of two versus three doses of quadrivalent HPV vaccine and associated effectiveness against condyloma in Sweden: a nationwide cohort study</atitle><jtitle>BMJ open</jtitle><addtitle>BMJ Open</addtitle><date>2017-06-01</date><risdate>2017</risdate><volume>7</volume><issue>6</issue><spage>e015021</spage><epage>e015021</epage><pages>e015021-e015021</pages><issn>2044-6055</issn><eissn>2044-6055</eissn><abstract>ObjectiveTo assess incidence of condyloma after two doses of quadrivalent human papillomavirus (qHPV) vaccine, by time since first vaccine dose, in girls and women initiating vaccination before age 20 years.DesignRegister-based nationwide open cohort study.SettingSweden.ParticipantsGirls and women initiating qHPV vaccination before age 20 years between 2006 and 2012. The study cohort included 264 498 girls, of whom 72 042 had received two doses of qHPV vaccine and 185 456 had received all three doses.Main outcome measureIncidence rate ratios (IRRs) of condyloma estimated by time between first and second doses of qHPV in months (m) and age at vaccination, adjusted for attained age.ResultsFor girls first vaccinated with two doses before the age of 17 years, the IRR of condyloma for 0–3 months between the first and second doses was 1.96 (95% CI 1.43 to 2.68) as compared with the standard three-dose schedule. The IRRs were 1.27 (95% CI 0.63 to 2.58) and 4.36 (95% CI 2.05 to 9.28) after receipt of two doses with 4–7 months and 8+ months between doses, respectively. For women first vaccinated after the age of 17 years, vaccination with two doses of qHPV vaccine and 0–3 months between doses was associated with an IRR of 2.12 (95% CI 1.62 to 2.77). For an interval of 4–7 months between doses, the IRR did not statistically significantly differ to the standard three-dose schedule (IRR=0.81, 95% CI 0.36 to 1.84). For women with 8+ months between dose 1 and dose 2 the IRR was 3.16 (95% CI 1.40 to 7.14).ConclusionA two-dose schedule for qHPV vaccine with 4–7 months between the first and second doses may be as effective against condyloma in girls and women initiating vaccination under 20 years as a three-dose schedule. Results from this nationwide study support immunogenicity data from clinical trials.</abstract><cop>England</cop><pub>BMJ Publishing Group LTD</pub><pmid>28600369</pmid><doi>10.1136/bmjopen-2016-015021</doi><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 2044-6055 |
| ispartof | BMJ open, 2017-06, Vol.7 (6), p.e015021-e015021 |
| issn | 2044-6055 2044-6055 |
| language | eng |
| recordid | cdi_swepub_primary_oai_swepub_ki_se_496203 |
| source | BMJ Open Access Journals; MEDLINE; DOAJ Directory of Open Access Journals; Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals; PubMed Central; SWEPUB Freely available online; PubMed Central Open Access |
| subjects | Adolescent Adult Age Cancer Child Cohort analysis Cohort Studies Condylomata Acuminata - epidemiology Condylomata Acuminata - prevention & control Disease Drug dosages Emigration Epidemiology Female Girls Health surveillance Human papillomavirus Humans Immunization Schedule Incidence Papillomavirus Infections - prevention & control Papillomavirus Vaccines - administration & dosage Population Public health Socioeconomic factors Sweden - epidemiology Systematic review Vaccines Womens health Young Adult |
| title | Timing of two versus three doses of quadrivalent HPV vaccine and associated effectiveness against condyloma in Sweden: a nationwide cohort study |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-05T22%3A35%3A14IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_swepu&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Timing%20of%20two%20versus%20three%20doses%20of%20quadrivalent%20HPV%20vaccine%20and%20associated%20effectiveness%20against%20condyloma%20in%20Sweden:%20a%20nationwide%20cohort%20study&rft.jtitle=BMJ%20open&rft.au=F,%20Lamb&rft.date=2017-06-01&rft.volume=7&rft.issue=6&rft.spage=e015021&rft.epage=e015021&rft.pages=e015021-e015021&rft.issn=2044-6055&rft.eissn=2044-6055&rft_id=info:doi/10.1136/bmjopen-2016-015021&rft_dat=%3Cproquest_swepu%3E2664174124%3C/proquest_swepu%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1907722501&rft_id=info:pmid/28600369&rfr_iscdi=true |